NDC 10019-944-50 - CYCLOPHOSPHAMIDE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 10019-944
- Requested NDC
- 10019-944-50
- Package NDCs from labels
- 10019-944-50, 10019-944-01
- Manufacturer
- Baxter Healthcare Company
- Effective date
- 2017-03-15
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CYCLOPHOSPHAMIDE - Baxter Healthcare Company | Baxter Healthcare Company | 2017-03-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 10019-944-01 | CYCLOPHOSPHAMIDE | 1 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 1 | 15 | |
| 10019-944-50 | CYCLOPHOSPHAMIDE | 50 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 50 | 15 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 10019-944-01 | EA - Each | 10019-944 | f3d382ad-80b6-45b2-a131-c224e6cbb4d9 | 1 | 2015-01-05 |
| 10019-944-50 | EA - Each | 10019-944 | d2d586f9-63c6-4409-bcf2-8eb4bbc25d79 | 1 | 2015-04-03 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | ACTIVE INGREDIENT | 8N3DW7272P | CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION [BAXTER HEALTHCARE CORPORATION] | 2 | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ACTIVE MOIETY | 6UXW23996M | CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION [BAXTER HEALTHCARE CORPORATION] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Nexus Pharmaceuticals, LLC | c961a1ac-6705-4756-9abc-9d84a6fcb5c8 | 2026-09-03 | Warnings, Adverse reactions | 8N3DW7272P |
| Frindovyx | CYCLOPHOSPHAMIDE | AVYXA Pharma, LLC | 5ad8ea65-4c98-487a-9c8d-df778765ec5e | 2026-08-26 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | OPKO Pharmaceuticals, LLC | d8057d1a-e8af-42ab-9da2-b545730b2655 | 2026-05-04 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | OPKO Pharmaceuticals, LLC | 7d6447e3-22c9-48d9-87c0-d0b576d7ea9e | 2026-04-21 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | BluePoint Laboratories | 1d3396d8-4c03-4a28-890a-d87c6c53a74e | 2026-03-12 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | BluePoint Laboratories | d7e97b99-83db-42d0-8521-b87fe6467a67 | 2026-02-12 | Warnings, Adverse reactions | ANDA040745 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Avenacy, LLC | 1de02105-9c5b-4d11-bddf-bf8450d88b78 | 2026-02-01 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Amneal Pharmaceuticals LLC | 520bfe39-dfd5-4a20-9a37-80078afded0d | 2026-01-19 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Bamboo US Bidco LCC | 2873b99a-830d-0a7b-e063-6394a90a4de7 | 2025-12-03 | Warnings, Adverse reactions | ANDA040745 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Epic Pharma, LLC | 988d2f71-1dc7-45b5-b2df-187e68224973 | 2025-11-17 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Civica, Inc. | 8627c83f-c057-495d-9f78-8b67bda97b3e | 2025-10-24 | Warnings, Adverse reactions | ANDA040745 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | 591d9955-3d9c-4cdc-a308-2f1288376b9f | 2025-06-24 | Warnings, Adverse reactions | ANDA040745 1734921 1734917 1734919 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | 97ab446f-5017-4180-ae65-0a355289b0ed | 2025-06-20 | Warnings, Adverse reactions | ANDA040745 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Eugia US LLC | 3c1eb470-0bba-457d-94e3-b9508f0d398a | 2025-04-21 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE FOR INJECTION | Slate Run Pharmaceuticals, LLC | 20bda486-cb9a-4d67-8c41-50e9fd066434 | 2025-04-02 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Sandoz Inc. | 0e9e22fa-178a-42fc-9f82-c303db3b245a | 2025-03-05 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Sagent Pharmaceuticals | 329b5a3a-c7b9-4b11-abf0-009719cdfb79 | 2025-01-22 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Cipla USA Inc. | 0e1cb955-99c8-4fe5-89d1-399c8e52174e | 2025-01-10 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE FOR INJECTION | Hainan Poly Pharm. Co., Ltd. | 6fde2705-a2d8-4d48-9618-b9d99d051373 | 2025-01-03 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Sandoz Inc | cf2f4b95-0327-499a-a5a3-51b1bdef68c5 | 2024-12-30 | Warnings, Adverse reactions | 8N3DW7272P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.